Oxaliplatin Deltapharma (Oxaliplatin)

Oxaliplatin Deltapharma is a platinum‑based agent used in the treatment of cancers that arise from the gastrointestinal tract.

• Colorectal cancer: improves the overall response and disease‑control rates when combined with fluoropyrimidine‑based regimens.
• Gastric cancer: used in combination chemotherapy protocols to enhance tumor shrinkage.
• Pancreatic cancer: added to multi‑drug regimens to increase progression‑free survival.
• Esophageal cancer: contributes to tumor response in multimodal treatment plans.
• Peritoneal carcinomatosis: employed as part of hyper‑hyper‑hyper HI‑HI regional therapy approaches.
• Metastatic adenoc t  t  t  t  t.

• Oxaliplatin forms reactive platinum‑DNA adducts that cause intra‑ and interstrand cross‑links, disrupting DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, particularly in rapidly dividing tumor cells, while sparing most normal tissues at therapeutic doses.

Oxaliplatin may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: frequent gastrointestinal upset during or after infusion.
• Peripheral neuropathy: tingling or numbness in the hands and feet, often dose‑related.
• Diarrhea: watery stools that may require supportive care.
• Fatigue: generalized tiredness experienced during treatment cycles.
• Thrombocytopenia: reduced platelet count observed in blood tests.
• Elevated liver enzymes: mild increases in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis‑like symptoms requiring immediate medical intervention.
• Acute hemolytic anemia: rapid destruction of red blood cells.
• Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea.
• Renal impairment: decreased kidney function noted in laboratory monitoring.
• Cardiac arrhythmias: irregular heart rhythms observed during infusion.
• Secondary malignancies: rare development of new cancers after prolonged exposure.

When using Oxaliplatin Deltapharma, clinicians should follow established safety protocols and monitor patients closely.

• Pre‑infusion assessment: evaluate renal, hepatic and hematologic function before each dose.
• Hydration: ensure adequate intravenous fluids to reduce nephrotoxicity risk.
• Neuropathy monitoring: assess sensory changes regularly and adjust dosing if needed.
• Pregnancy and lactation: avoid use; discuss risks with patients of child‑bearing potential.
• Drug interactions: review concomitant medications for potential additive toxicities.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Oxaliplatin may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage.
• Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia.
• High‑dose vitamin C: may reduce platinum‑DNA binding effectiveness.

Moderate Interactions (Monitor Closely)

• Antiemetics (e.g., ondansetron): may require dose adjustment for optimal control of nausea.
• CYP450 inducers (e.g., rifampicin): potential impact on drug clearance.
• Immunosuppressants (e.g., cyclosporine): monitor for enhanced myelosuppression.